231 related articles for article (PubMed ID: 30706224)
21. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
22. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
23. Only estrogen receptor "positive" is not enough to predict the prognosis of breast cancer.
Ryu JM; Choi HJ; Kim I; Lee SK; Yu J; Kim JE; Kang BI; Lee JE; Nam SJ; Kim SW
Breast Cancer Res Treat; 2018 Dec; 172(3):627-636. PubMed ID: 30218195
[TBL] [Abstract][Full Text] [Related]
24. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
25. Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Howell SJ; Wardley AM; Armstrong AC
J Natl Cancer Inst; 2009 Dec; 101(24):1730; author reply 1730-1. PubMed ID: 19893007
[No Abstract] [Full Text] [Related]
26. Prediction of Oncotype Dx recurrence score using clinical parameters: A comparison of available tools and a simple predictor based on grade and progesterone receptor.
Thibodeau S; Voutsadakis IA
Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):89-96. PubMed ID: 30796885
[TBL] [Abstract][Full Text] [Related]
27. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
28. 21-Gene Recurrence Score Testing in HER2-positive Patients.
Altman AM; Marmor S; Tuttle TM; Hui JYC
Clin Breast Cancer; 2019 Apr; 19(2):126-130. PubMed ID: 30595493
[TBL] [Abstract][Full Text] [Related]
29. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
[TBL] [Abstract][Full Text] [Related]
31. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.
Geradts J; Bean SM; Bentley RC; Barry WT
Cancer Invest; 2010 Nov; 28(9):969-77. PubMed ID: 20873988
[TBL] [Abstract][Full Text] [Related]
32. Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.
Ueno T; Saji S; Chiba T; Kamma H; Isaka H; Itoh H; Imi K; Miyamoto K; Tada M; Sasano H; Toi M; Imoto S
Tumour Biol; 2018 Nov; 40(10):1010428318811025. PubMed ID: 30841783
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
[TBL] [Abstract][Full Text] [Related]
34. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
35. From the guest editor: Triple-negative breast cancer.
Hudis CA
Cancer J; 2010; 16(1):10-1. PubMed ID: 20164684
[No Abstract] [Full Text] [Related]
36. New approaches for triple-negative breast cancer.
Oncology (Williston Park); 2012 Oct; 26(10):916, 931, 935. PubMed ID: 23175999
[No Abstract] [Full Text] [Related]
37. Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.
Reyes SA; De La Cruz LM; Ru M; Pisapati KV; Port E
Ann Surg Oncol; 2019 Oct; 26(10):3397-3408. PubMed ID: 31429016
[TBL] [Abstract][Full Text] [Related]
38. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
39. Is there a role of breast pathologist in diagnostic challenges of discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis?
Altundag K
J Neurooncol; 2018 May; 138(1):219. PubMed ID: 29383648
[No Abstract] [Full Text] [Related]
40. Targeted Combinations for Hormone Receptor-Positive Advanced Breast Cancer: Who Benefits?
Johnston SR
J Clin Oncol; 2016 Feb; 34(5):393-5. PubMed ID: 26700117
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
